SAN DIEGO--(BUSINESS WIRE)--Cytonus Therapeutics Inc., a biotechnology company developing new platforms for delivering biologics, announced today that it will be presenting preclinical data for its Cargocyte™ technology platform program targeting difficult to treat Breast Cancer at the BIO International Convention meeting June 3-6 in Philadelphia, PA.
Cargocytes are engineered allogenic cell lines that can carry a variety of payloads like small molecule compounds, gene editing therapies, therapeutic RNAs, and powerful biologics such as immune modulating cytokines, antibodies and oncolytic viruses.
“We are honored to have been selected to present Cytonus’ first-of-its-kind Cargocyte™ technology platform at this year’s BIO convention and look forward to sharing our promising CA-IL12 data in treating Triple Negative Breast Cancer in preclinical animal models,” said Remo Moomiaie-Qajar, M.D., president and CEO of Cytonus.
Details of the presentation:
|Company Name:||Cytonus Therapeutics, Inc.|
|Presentation Date:||Thursday, June 6|
|Presentation Time:||1:30:00 PM|
|Presentation Room:||Theater 1|
|Speaker:||Remo Moomiaie-Qajar, M.D., CEO|
Cytonus Therapeutics, Inc.
Cytonus Therapeutics Inc. is a biopharmaceutical company developing a next-generation Adoptive Cellular Transport platform called Cargocytes™. The San Diego-based company’s proprietary Cargocyte™ platform consists of cellular-engineered transporters of a multiplicity of therapeutic payloads to tissue in a selective, controllable and potent off-the-shelf cellular therapy for the potential treatment of several disease across multiple therapeutic areas. Cytonus’ initial focus is to advance Cargocyte™ candidates for the treatment of rare and difficult to treat cancers and inflammatory diseases. For more information, visit www.cytonus.com or follow us on LinkedIn.
Statements in this news release, which relate to other than strictly historical facts, such as statements about Cytonus’ plans and strategies, new and existing products and technologies, anticipated clinical and regulatory pathways, and markets for its products are forward-looking statements. The words "believe," "expect," "anticipate," "estimate," "project," and similar expressions identify forward-looking statements that speak only as of the date hereof. Such statements involve risks and uncertainties that could cause actual results to differ materially from anticipated results due to many factors, including regulatory and development risks. Cytonus undertakes no obligation to publicly update or revise any forward-looking statements. This news release is neither an offer to sell, nor the solicitation of any offer to purchase, any security.